<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03043521</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_APA_105</org_study_id>
    <nct_id>NCT03043521</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Properties of CJ-12420 on Evening Dosing</brief_title>
  <official_title>Phase I Study to Investigate Pharmacodynamics of CJ-12420 Compared to Dexlansoprazole With Evening Dosing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare and evaluate impact on pharmacodynamic
      characteristics of CJ-12420 and dexlansoprazole with evening dosing in healthy male
      volunteers
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation Criteria:

        1. Pharmacokinetic Endpoints Cmax, tmax, AUClast of CJ-12420

        2. Pharmacodynamics Endpoints Time pH &gt; 4 Time pH &gt; 6 Integrated acidity Percent inhibition
           of integrated acidity Percent inhibition time gastric pH ≤ 4 Median pH

        3. Safety Assessments Physical examination, ECGs, vital signs (blood pressure, heart rate,
           body temperature), laboratory test (CBC, Chemistry, UA), and adverse events (AEs)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2015</start_date>
  <completion_date type="Actual">August 12, 2015</completion_date>
  <primary_completion_date type="Actual">August 12, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time pH &gt; 4 of CJ-12420</measure>
    <time_frame>24 hours pH</time_frame>
    <description>intragastric pH</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of CJ-12420</measure>
    <time_frame>up to 20 hours</time_frame>
    <description>maximum measured plasma concentraion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of CJ-12420</measure>
    <time_frame>up to 20 hours</time_frame>
    <description>The area under the plasma concentration versus time curve from time 0 to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of dexlansoprazole</measure>
    <time_frame>up to 20 hours</time_frame>
    <description>maximum measured plasma concentraion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUClast of dexlansoprazole</measure>
    <time_frame>up to 20 hours</time_frame>
    <description>The area under the plasma concentration versus time curve from time 0 to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time pH &gt; 4 of dexlansoprazole</measure>
    <time_frame>24 hours pH</time_frame>
    <description>intragastric pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median pH &gt; 4 of CJ-12420</measure>
    <time_frame>24 hours pH</time_frame>
    <description>intragastric pH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median pH &gt; 4 of dexlansoprazole</measure>
    <time_frame>24 hours pH</time_frame>
    <description>intragastric pH</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>CJ-12420 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T1=CJ-12420 50mg QD evening (9PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T2=CJ-12420 100mg QD evening (9PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CJ-12420 200mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>T3=CJ-12420 200mg QD evening (9PM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexlansopazole 60mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R=dexlansoprazole 60mg QD evening (9p.m)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexlansoprazole 60 MG</intervention_name>
    <arm_group_label>Dexlansopazole 60mg</arm_group_label>
    <other_name>R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 50mg</intervention_name>
    <arm_group_label>CJ-12420 50mg</arm_group_label>
    <other_name>T1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 100mg</intervention_name>
    <arm_group_label>CJ-12420 100mg</arm_group_label>
    <other_name>T2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CJ-12420 200mg</intervention_name>
    <arm_group_label>CJ-12420 200mg</arm_group_label>
    <other_name>T3</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male volunteers aged ≥20 to ≤45 years

          2. Body mass Index (BMI) of 19 to 28kg/m2 ; and a total body weight ≥ 50kg

          3. Medically healthy without clinically significant vital signs (blood pressure in
             sitting position, heart rate)

               -  90 mmHg ≤ Systolic blood pressure (SBP) ≤ 140 mmHg

               -  50 mmHg ≤ Diastolic blood pressure (DBP) ≤ 95 mmHg

               -  45 (beats/min) ≤ Heart rate ≤ 95 (beats/min)

          4. Understand restriction during the study and voluntarily consent to participate in the
             study

          5. Consent to use the effective contraceptive methods (using abstinence, spermicide, and
             condom) and not to donate sperm during the study and until 30 days after completion of
             study

          6. Non-smoker or ex-smoker who stopped smoking for at least one year

          7. Negative H. pylori result in urea breath test (UBT)

        Exclusion Criteria:

          1. History of clinically significant diseases in the digestive, kidney, liver, nervous,
             hemato-oncologic, endocrine, respiratory, immune, psychiatric, musculoskeletal, or
             cardiovascular system and other diseases that may harm safety of the subject or may
             affect the validity of study results, in the judgment of investigator

          2. History of allergy or hypersensitivity to any drugs including serious adverse events
             from treatments such as PPI (omeprazole, rabeprazole, lansoprazole) or P-CAB

          3. History surgery that may affect absorption, distribution, metabolism, and elimination
             of the study drug or in such a medical condition, at the discretion of the principal
             investigator or sub-investigator

          4. History of use of another investigational product within 90 days prior to screening
             visit

          5. Donation of a unit of whole blood within 60 days or blood components or transfusion
             within 30 days prior to screening visit

          6. Having special diet or changes in dietary habits within 30 days prior to screening
             visit

          7. Use of prescription drug within 14 days or over-the-count (OTC) drug including herbal
             medicine within 7 days prior to screening visit

          8. Alcohol &gt; 21 units/week

          9. Caffeinated drink intake &gt; 5units/day

         10. Positive on urinary drug screening test or urine nicotine test

         11. Positive human immunodeficiency virus (HIV), hepatitis B, hepatitis C, or syphilis
             test

         12. Clinically significant abnormal result of liver function (serum ALT, AST or total
             bilirubin levels ≥ 1.5 times the upper limit of normal (ULN))

         13. Inability to tolerate pH catheter insertion

         14. History of symptomatic GERD, erosive esophagitis (EE), duodenal ulcer, gastric ulcer,
             Barrett's esophagus, or Zollinger-Ellison Syndrome

         15. Any other conditions which would have made the subject unsuitable for the study in the
             opinion of the investigator
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Healthy male volunteers</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eunji Kim</last_name>
    <role>Study Director</role>
    <affiliation>CJ HealthCare Corp.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Lansoprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

